HeartCore Executes Content Management System Deal with GMO MAKESHOP

NEW YORK and TOKYO, Sept. 28, 2022 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc., (“HeartCore” or “the Company”), a leading software development company, announced that it has signed a deal with GMO MAKESHOP Co. Ltd. (“GMO MAKESHOP”), offering its Content Management System (“CMS”) to help augment GMO MAKESHOP’s digital transformation efforts prior to the launch of its Cloud E-Commerce Plan.

HeartCore’s CMS is one of the top rated software systems in Japan, as it provides a secure all-in-one package that includes marketing, sales, service, and content management systems as well as other tools and integrations that enable companies to attract and engage customers throughout the customer lifecycle. With the capabilities of the Company’s CMS, businesses operating e-commerce sites using GMO MAKESHOP’s Cloud E-Commerce Plan will now be able to centrally manage content across several of their business units, as well as implement marketing measures that are optimal for each user on each site. Additionally, on the back end, the GMO MAKESHOP team will be able to leverage key tools to manage sales promotions, track inventory and product management, and also deliver management functions for its e-commerce initiative. HeartCore will also provide GMO MAKESHOP with process mining and task mining capabilities to optimize its operations.

“We are pleased to play an integral role in GMO MAKESHOP’s Cloud E-Commerce Plan by licensing our industry leading CMS,” said CEO Sumitaka Yamamoto. “Our software will allow their team to seamlessly launch a full scale e-commerce platform that provides state-of-the-art capabilities both on the front and back end, especially as they manage a multitude of websites. HeartCore provides a safe and secure platform and an all-in-one support team that is always ready to assist our customers. We look forward to assisting GMO MAKESHOP and ramping up sales efforts with our leading enterprise software technology.”

About HeartCore Enterprises, Inc.

Headquartered in Tokyo, Japan, HeartCore Enterprises is a leading software development company offering Software as a Service (SaaS) solutions to enterprise customers in Japan and worldwide. The Company also provides data analytics services that allow enterprise businesses to create tailored web experiences for their clients through best-in-class design. HeartCore’s customer experience management platform (CXM Platform) includes marketing, sales, service and content management systems, as well as other tools and integrations, which enable companies to enhance the customer experience and drive engagement. HeartCore also operates a digital transformation business that provides customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises. Additional information about the Company’s products and services is available at www.heartcore.co.jp and https://heartcore-enterprises.com/.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in HeartCore’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond HeartCore’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects HeartCore’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. HeartCore assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

HeartCore Investor Relations Contact:

Gateway Group, Inc.
Matt Glover and John Yi
[email protected]
(949) 574-3860



Datasea Reports Full Fiscal Year 2022 Financial Results with Record Sales Orders and Revenue

BEIJING, Sept. 28, 2022 (GLOBE NEWSWIRE) — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), incorporated in Nevada in September 2014, is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city in China, today announced financial results for its full fiscal year ended June 30, 2022, and provided an update on its key strategic and operational initiatives. The Company will host a conference call and webcast to discuss its financial results today at 9 a.m. ET (9 p.m. Beijing and Hong Kong Time).

“This year marked an important moment in Datasea’s history. We launched 5G messaging solutions and introduced acoustic intelligence to the market, which combined with our original smart city offerings, broadened the ecosystem and expanded the total addressable market,” said Zhixin Liu, CEO of Datasea.

Mrs. Liu continued, “Our business revenue for the fiscal year ended June 30, 2022 continued to be strong at 9,653% compared to the fiscal year ended June 30, 2021, mainly driven by the 5G messaging business. The investments we have made in both technology and product rollouts in promising areas are enhancing our competitive positioning, and will also add new revenue resources, such as the acoustic intelligence business, in the new fiscal year. Our growth strategies are designed to fortify our position and build on our market share gains including our efforts around key product innovation, effective marketing and merchandising strategies, and productivity improvement.”

Full Year Financial Highlights

  • Revenue was $17,080,911 for the year ended June 30, 2022, compared to $175,138 for the year ended June 30, 2021, representing an increase of $16,905,773, or 9,653%.
  • Gross profit was $955,673 for the year ended June 30, 2022, compared to $94,003. for the year ended June 30, 2021, representing an increase of $861,670 or 917%. The increase in gross profit was mainly due to the delivery of services related to the 5G SMS service platform in 2022.
  • R&D expenses were $1,259,739 for the year ended June 30, 2022, compared to $851,839 for the year ended June 30, 2021.
  • Approximately $41.72 million worth of 5G messaging business contracts have been signed, which the company expects to receive in increments over the course of the next fiscal year however there cannot be any assurance of when the full amount will be received if at all.

Full Year Business Highlights

5G Messaging

  • Client expansion. Datasea’s 5G messaging solutions have been adopted by leading companies across 11 industries, including express, health care, retail, tourism and more.
  • Marketing and sales expansion. Datasea is one of the first movers in the 5G messaging industry and has built a comprehensive 5G messaging product portfolio with high brand recognition. The Company adopted an integrated sales strategy to boost sales to better promote business development and meet with the demand of customers, which includes 1) an expansion of the sales team for direct sales; 2) partner and broker mode; 3) joint marketing mode; 4) the enterprise key customer project cooperation mode.
  • Industry recognition. As an industry leader, Datasea has been actively involved in the discussion and formulation of 5G messaging regulations and application standards. In March 2022, Datasea joined SF Express in the drafting of the “5G Messaging Blue Book” on the express industry initiated by the Ministry of Industry and Information Technology Institute. In June 2022, Datasea participated in the drafting of the “5G Messaging Development White Paper” jointly issued by the China Academy of Information and Communication Technology and the China Association of Communication Enterprises.

Acoustic Intelligence

Datasea is an acoustic intelligence trailblazer and aims to introduce this cutting-edge technology and its applications to China and the world. Company demonstrated the commercial potential of acoustic intelligence, through direct sales of acoustic intelligence powered disinfection equipment and agreements with different businesses to apply acoustic intelligence in the areas such as automotive systems and smart home appliances.

  • Client expansion. The Company worked with Shanghai Zhuifeng Automotive System Co., Ltd to promote the acoustic intelligent module products in vehicle application scenarios. Datasea added Jiangsu Xinrong Network Technology Research Institute Co., Ltd. as a new customer of acoustic intelligence powered disinfection equipment and the total value of the engagement would be RMB 20 million (approximately USD 3.14 million) over the course of the two-year agreement.
  • Marketing and sales expansion. Datasea’s acoustic intelligent products are provided to businesses and retail customers. Datasea developed partnerships on innovation and joint research and development to explore new opportunities. Examples include using acoustic intelligence in precision manufacturing, home appliances and other industries. Other than Chinese market, Datasea also formed partnerships with companies like Unicorner LLC and Shenzhen New Route Network Technology to expand distribution in global market.
  • Industry recognition. Datasea released China’s inaugural white paper with co-authors, to uncover detailed facts and compelling analyses of the acoustic-intelligence technology, commercial applications, and the industry outlook. Datasea’s acoustic intelligence technology has obtained nine software copyrights from the Government of China, and seven patents from the Government of China related to acoustic intelligence powered disinfection technology are pending approval.

Smart City

  • Client expansion. The Company provided smart city solutions to office buildings, schools, and residential communities. Agreement with Eastcom Smart Chain (Beijing)
  • Product update. The Company recently laid out a series of upgrades, including an all-in-one machine to provide functions including temperature measurement and health code reading, IoT cloud platform 2.0 and Campus Security Cloud System to meet with the client needs in different scenarios and enhance the system’s analysis efficiency and integration capability.

Webcast and Conference Call Information

The Company will host a conference call and webcast to discuss its financial results today at 9 a.m. ET (9 p.m. Beijing and Hong Kong Time).

Dial-in details for the earnings conference call are as follows:
Toll Free: 1-877-451-6152
Toll/International: 1-201-389-0879

Participants should dial-in at least 5 minutes before the scheduled start time. Additionally, a live and archived webcast of the conference call will be available at: https://viavid.webcasts.com/starthere.jsp?ei=1573666&tp_key=436d1f4157

A replay of the conference call will be accessible approximately soon after the conclusion of the live, by dialing the following telephone numbers:
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 13733271
Replay Start: Wednesday September 28, 2022, 12:00 PM ET
Replay Expiry: Wednesday October 5, 2022, 11:59 PM ET

About Datasea Inc.

Datasea Inc., through its variable interest entity, Shuhai Information Technology Co., Ltd., a digital technology company in China, engages in three converging and innovative industries: smart city, acoustic intelligence and 5G messaging. Datasea leverages facial recognition technology and other visual intelligence algorithms, combined with cutting-edge acoustic and non-visual intelligence algorithms, to provide smart city solutions that meet the security needs of residential communities, schools and commercial enterprises. Most recently, in response to the growing utilization of 5G technologies and the overall initiative to utilize Datasea’s technology capabilities to expand business coverage and revenue resources, Datasea has also strategically expanded business coverage to 5G messaging and smart payment solutions. Datasea has been certified as one of the High-Tech Enterprises (jointly issued by the Beijing Science and Technology Commission, Beijing Finance Bureau, Beijing State Taxation Bureau and Beijing Local Taxation Bureau) and one of the Zhongguancun High Tech Enterprises (issued by the Zhongguancun Science Park Administrative Committee) in recognition of the company’s achievement in high technology products. For additional company information, please visit: www.dataseainc.com. Datasea routinely posts important information on its website.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Datasea investor and media Contact:

International Elite Capital Inc.
Annabelle Zhang
Telephone: +1(646) 866-7989
Email: [email protected] 

DATASEA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    YEARS ENDED JUNE 30,  
    2022     2021  
             
Revenues   $ 17,080,911     $ 175,138  
Cost of goods sold     16,125,238       81,135  
                 
Gross profit     955,673       94,003  
                 
Operating expenses                
Selling     1,358,203       568,034  
General and administrative     5,574,985       3,535,416  
Research and development     1,259,739       851,839  
                 
Total operating expenses     8,192,927       4,955,289  
                 
Loss from operations     (7,237,254 )     (4,861,286 )
                 
Non-operating income (expenses)                
Other income (expenses)     75,075       (25,547 )
Interest income     50,497       2,517  
                 
Total non-operating income (expenses), net     125,572       (23,030 )
                 
Loss before income tax     (7,111,682 )     (4,884,316 )
                 
Income tax            
                 
Loss before noncontrolling interest     (7,111,682 )     (4,884,316 )
                 
Less: loss attributable to noncontrolling interest     (589,974 )     (235,839 )
                 
Net loss to the Company     (6,521,708 )     (4,648,477 )
                 
Other comprehensive item                
Foreign currency translation gain attributable to the Company     10,337       103,043  
Foreign currency translation loss attributable to noncontrolling interest     (22,356 )     (6,104 )
                 
Comprehensive loss attributable to the Company   $ (6,511,371 )   $ (4,545,434 )
                 
Comprehensive loss attributable to noncontrolling interest   $ (612,330 )   $ (241,943 )
                 
Basic and diluted net loss per share   $ (0.27 )   $ (0.22 )
                 
Weighted average shares used for computing basic and diluted loss per share     23,956,393       21,279,004  

DATASEA INC.

CONSOLIDATED BALANCE SHEETS

    JUNE 30, 2022     JUNE 30, 2021  
             
ASSETS            
CURRENT ASSETS            
Cash   $ 164,217     $ 49,676  
Accounts receivable     259,410       1,856  
Inventory     211,353       194,264  
Value-added tax prepayment     46,509       171,574  
Prepaid expenses and other current assets     575,312       468,615  
Total current assets     1,256,801       885,985  
                 
NONCURRENT ASSETS                
Security deposit for rents     17,181       256,987  
Long term investment     29,800        
Property and equipment, net     187,831       309,408  
Intangible assets, net     1,741,791       1,092,147  
Right-of-use assets, net     522,273       1,350,590  
Total noncurrent assets     2,498,876       3,009,132  
                 
TOTAL ASSETS   $ 3,755,677     $ 3,895,117  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
CURRENT LIABILITIES                
Accounts payable   $ 197,573     $ 174,718  
Unearned revenue     289,888       189,527  
Deferred revenue           46,439  
Accrued expenses and other payables     994,884       561,674  
Due to related party     102,331       69,305  
Loans payable     81,950       1,486,819  
Operating lease liabilities     457,949       730,185  
Total current liabilities     2,124,575       3,258,667  
                 
NONCURRENT LIABILITIES                
Operating lease liabilities     31,470       558,739  
Total noncurrent liabilities     31,470       558,739  
                 
TOTAL LIABILITIES     2,156,045       3,817,406  
                 
COMMITMENTS AND CONTINGENCIES                
                 
STOCKHOLDERS’ EQUITY                
Common stock, $0.001 par value, 375,000,000 shares authorized,
24,324,633 and 21,474,138 shares issued and outstanding as of June 30,
2022 and 2021, respectively
    24,325       21,474  
Additional paid-in capital     20,729,559       12,086,788  
Accumulated comprehensive income     283,587       273,250  
Accumulated deficit     (18,583,566 )     (12,061,858 )
TOTAL COMPANY STOCKHOLDERS’ EQUITY     2,453,905       319,654  
                 
Noncontrolling interest     (854,273 )     (241,943 )
                 
TOTAL EQUITY     1,599,632       77,711  
                 
TOTAL LIABILITIES AND EQUITY   $ 3,755,677     $ 3,895,117  

DATASEA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

  

    YEARS ENDED JUNE 30,  
    2022     2021  
             
Cash flows from operating activities:            
Loss including noncontrolling interest   $ (7,111,682 )   $ (4,884,316 )
Adjustments to reconcile loss including noncontrolling interest to net cash used in operating activities:                
Loss on disposal on fixed assets     916       9,698  
Depreciation and amortization     577,822       199,232  
Bad debt expense     284,958       277,639  
Inventory impairment           10,837  
Operating lease expense     863,691       809,630  
Stock compensation expense     642,000       21,000  
Changes in assets and liabilities:                
Accounts receivable     (267,771 )     (613 )
Inventory     (25,323 )     33,169  
Value-added tax prepayment     123,313       (92,709 )
Prepaid expenses and other current assets     (224,285 )     (66,982 )
Accounts payable     26,236       122,641  
Unearned revenue     111,689       165,462  
Deferred revenue     (46,461 )     42,168  
Accrued expenses and other payables     741,328       222,808  
Payment on operating lease liabilities     (836,143 )     (818,013 )
                 
Net cash used in operating activities     (5,139,712 )     (3,948,349 )
                 
Cash flows from investing activities:                
Acquisition of property and equipment     (51,340 )     (142,537 )
Acquisition of intangible assets     (1,051,111 )     (26,148 )
Long-term investment     (30,973 )      
                 
Net cash used in investing activities     (1,133,424 )     (168,685 )
                 
Cash flows from financing activities:                
Due to related parties     37,042       68,541  
(Payment) proceeds of loans payable     (1,402,336 )     1,449,306  
Proceeds from capital contribution from a major shareholder     62,802        
Net proceeds from issuance of common stock     7,681,796       931,000  
                 
Net cash provided by financing activities     6,379,304       2,448,847  
                 
Effect of exchange rate changes on cash     8,373       51,927  
                 
Net increase (decrease) in cash     114,541       (1,616,260 )
                 
Cash, beginning of year     49,676       1,665,936  
                 
Cash, end of year   $ 164,217     $ 49,676  
                 
Supplemental disclosures of cash flow information:                
Cash paid for interest   $     $  
Cash paid for income tax   $     $  
                 
Supplemental disclosures of non-cash investing and financing activities:                
Transfer of prepaid software development expenditure to intangible assets   $ 50,000     $ 1,304,996  
Right-of-use assets obtained in exchange for new operating lease liabilities   $     $ 1,100,000  
Shares issued for accrued bonus to officers   $ 259,023     $  

IMPORTANT NOTICE TO USERS (summary only, please refer to the Form 10-K for full text of notice); All information is unaudited unless otherwise noted or accompanied by an audit opinion and is subject to the more comprehensive information contained in our SEC reports and filings. We do not endorse third-party information. All information speaks as of the last fiscal quarter or year for which we have filed a Form 10-K or 10-Q, or for historical information the date or period expressly indicated in or with such information. We undertake no duty to update the information. Forward-looking statements are subject to risks and uncertainties described in our Forms 10-Q and 10-K.

 



E-Home Household Services Holdings Limited Announces Extraordinary General Meeting Results on Share Consolidation and Share Capital Increase

FUZHOU, China, Sept. 28, 2022 (GLOBE NEWSWIRE) — E-Home Household Service Holdings Limited (Nasdaq: EJH) (the “Company” or “E-Home”), a provider of integrated household services in China, today announced that at an extraordinary general meeting of the Company held on September 23, 2022, at 10:00 a.m., local time, at Floor 9, Building 14, HaixiBaiyue Town, No. 14 Duyuan Road, Luozhou Town, Cangshan District, Fuzhou City 350001, People’s Republic of China (the “Meeting”), its shareholders approved resolutions that would result in (i) a share consolidation of 20 issued and unissued ordinary and preferred shares with par value of US$0.0001 each in the Company’s issued and unissued share capital into one share with par value of US$0.002 (the “Share Consolidation”) and (ii) an increase in the authorized share capital of the Company from US$51,000 (divided in to 510,000,000 shares) to US$1,020,000 (divided in to 510,000,000 shares), all of which will rank pari passu in all respects with all existing shares of the Company. The Share Consolidation is primarily being effectuated to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) related to the minimum price per share of the Company’s ordinary shares. 

The Company will announce effectiveness of the Share Consolidation shortly. Immediately after the Share Consolidation, each stockholder’s percentage ownership interest in the Company and proportional voting power will remain unchanged, except for minor changes and adjustments that will result from the treatment of fractional shares. The rights and privileges of the holders of ordinary and preferred shares will be substantially unaffected by the Share Consolidation. No fractional shares will be issued in connection with the Share Consolidation, but all such fractional shares shall be redeemed in cash for the fair value of such fractional share, such fair value being the closing price of the ordinary shares on a post-consolidation basis on the applicable trading market on the first trading date of the ordinary shares following the Share Consolidation. Stockholders who are holding their shares in electronic form at brokerage firms do not need to take any action, as the effect of the Share Consolidation will automatically be reflected in their brokerage accounts.

About E-Home Household Service Holdings Limited

Established in 2014, E-Home Household Service Holdings Limited is a Nasdaq-listed household service company based in Fuzhou, China. The Company, through its website and WeChat platform “e家快服”, provides integrated household services, including 1) installation and maintenance of home appliances and smart homes; 2) Housekeeping, nanny, confinement nurse and cleaning services; 3) Internet elderly care + home-based elderly care; 4) Hospital care; 5) Nanny delivery platform.

After years of development, the Company has formed two main services and four auxiliary services targeting at individual consumers (ToC) and business clients (ToB). 1) The ToC business focuses on nanny, confinement nurse, home-based elderly care and cleaning, and family comprehensive service supplemented by other housekeeping services. At present, it has successfully connected with metaverse technology to realize metaverse-based customer service as well as training of domestic workers. The ToB business focuses on public cleaning and cleaning robotic equipment. Four auxiliary services include 1) docking and application of metaverse technology to housekeeping and cleaning industries; 2) online and offline sales of medicine and health food (including nannies and nursing workers); 3) training on nannies and nursing workers to engage in health care in physical stores; 4) human resources (flexible employment).

E-Home has become a modern enterprise of comprehensive service for family life. The Company always adheres to the business philosophy of “solving every issue of customers with heart”, and to the code of conduct of “doing everything well with heart”. The Company aims to set the benchmark of the household service industry. For more information, visit the Company’s website at http://www.ej111.com/ir.html.

Forward-Looking Statement

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors.

For more information, please contact:

Chunming Xie
Investor Relations
Email: [email protected]
Phone: +86 15359908086



The Most Accurate Flight Emissions Data Is Now Available via Cirium Sky

The Most Accurate Flight Emissions Data Is Now Available via Cirium Sky

  • Cirium’s CO2 emissions calculations, commended by American Airlines and Virgin Atlantic for accuracy, are now available in Cirium Sky
  • The Cirium Sky, aviation data warehouse, provides secure cloud access to Cirium’s comprehensive datasets
  • Cirium Sky democratizes data and unifies it in one place enabling it to drive operational efficiencies and faster decision making

NEW YORK–(BUSINESS WIRE)–
The air travel industry now has easy access to the most accurate carbon emissions data from the aviation analytics firm, Cirium, through its new aviation data warehouse, Cirium Sky.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005211/en/

The Most Accurate Flight Emissions Data Is Now Available via Cirium Sky (Photo: Business Wire)

The Most Accurate Flight Emissions Data Is Now Available via Cirium Sky (Photo: Business Wire)

Jeremy Bowen, CEO at Cirium said: “We developed Cirium Sky to offer a single-source solution to the market, where businesses can access Cirium’s extensive data warehouse in the cloud, at any time or place.

The level of precision and accuracy of Cirium’s CO2 emissions calculations for flights far exceeds estimates available today and accessing this data via Cirium Sky enables our clients to fulfill their sustainability objectives faster and more cost effectively.”

As the aviation industry rebuilds from the impact of the pandemic, the need for businesses to report on their Environment, Social and Governance (ESG) footprint has increasingly taken center stage.

Reducing aviation’s emissions will require for airlines, airports, Air Service Navigation Providers (ANSPs), aircraft financiers and manufacturers, and travel companies to use accurate data which considers many variables that can impact a flight’s emissions, including but not limited to, aircraft and engine specifications, airline schedules and actual flight operations.

Andrew O’Connor, VP of Journey and Sustainability at Cirium said: “We have seen a lack of consistency in the flight emissions reporting so far, which has driven less consensus on agreed metrics to be used to measure emissions effectively.

The Cirium team is on a mission to establish the standard for accurate carbon emissions data and are focused on historical and predicted fuel burn and emissions per aircraft, the flight and the cabin seat class. These building blocks are core to almost all aviation sustainability use cases.”

Cirium Sky leverages the latest technology to democratize data and unify it in one place to enable businesses to identify operational inefficiencies, lower costs, reduce financial risks, and identify new service opportunities.

With the availability of comprehensive historical and predicted aircraft fuel burn and CO2 emissions data, Cirium Sky offers the most complete and deepest range of aviation datasets in the industry, including global schedules and connections, flight status, air traffic management, weather, global aircraft fleet, and fares and passenger traffic.

The accuracy of Cirium’s data and analytics is supported by strong data partnerships with over 900 airlines, airports worldwide, ADS-B satellite tracking, Global Distribution Systems (GDS) and more.

Find out more about Cirium Sky.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.

For media enquiries:

Cirium media team: [email protected]

US: Mike Arnot at [email protected]

EMEA: The PC Agency at [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Sustainability Transportation Technology Travel Environment Data Analytics Air Transport Aerospace Environmental, Social and Governance (ESG) Manufacturing

MEDIA:

Logo
Logo
Photo
Photo
The Most Accurate Flight Emissions Data Is Now Available via Cirium Sky (Photo: Business Wire)

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

First-time Preview of the Ergo-Series of the OMNI® Surgical System and Exhibition of the New SION™ Surgical Instrument to be Showcased at AAO Booth 4843

MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago, IL. Meeting delegates are invited to attend the four sessions throughout the weekend at the Sight Sciences booth (#4843) to learn more about OMNI standalone treatment and engage directly with the panelists. Additionally, the soon to be released Ergo-Series of the OMNI Surgical System and the recently launched SION Surgical Instrument will be showcased at AAO 2022 and available for hands-on demos at the booth.

“The OMNI Surgical System has changed the way physicians approach glaucoma surgery,” said Cathleen McCabe, Chief Medical Officer of Eye Health America and Medical Director of The Eye Associates in Bradenton and Sarasota, FL. “As a minimally invasive, implant-free standalone treatment, OMNI allows surgeons to lower IOP and reduce a patient’s medication burden while avoiding more aggressive surgical interventions. Having such an effective and safe standalone intervention is vital to serve the needs of our phakic and pseudophakic patients with glaucoma.”

Speaker Forum on Saturday, October 1:

  • 11:00 AM – 11:45 PM CT: Standalone MIGS: Beyond Cataract Surgery
    • Leon Herndon, MD (moderator); Deb Ristvedt, DO; Arkadiy Yadgarov, MD
  • 1:30 PM – 2:15 PM CT: Standalone Use of the OMNI Surgical System
    • Cathleen McCabe, MD (moderator); Jason Bacharach, MD; Jai Parekh, MD

Speaker Forum on Sunday, October 2:

  • 10:00 AM – 10:45 AM CT: Why Standalone MIGS with the OMNI Surgical System?
    • Paul Singh, MD (moderator); Analisa Arosemena, MD; Amir Cohen, MD
  • 1:30 PM – 2:15 PM CT: Best practices in adopting Standalone MIGS
    • Nathan Radcliffe, MD (moderator); Matthew Brink, MD; Zarmeena Vendal, MD

“The growth and adoption of OMNI as a standalone treatment as evidenced by such a diverse and esteemed panel of speakers sharing their real-world experiences and clinical data, brings a sense of great anticipation to this year’s AAO meeting,” said Paul Badawi, CEO and co-founder of Sight Sciences. “We are also excited to demonstrate the continued evolution of our surgical portfolio by offering doctors hands-on access to the soon-to-be released Ergo-Series of the OMNI Surgical System and the new SION Surgical Instrument.”

Booth events are not part of the official AAO program. The 12 presenters are paid consultants of Sight Sciences.

About the OMNI Surgical System

The OMNI® Surgical System is a handheld, single-use therapeutic device for minimally invasive glaucoma surgery (MIGS). It is indicated for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

OMNI allows surgeons to access 360 degrees and three primary points of resistance of an eye’s diseased conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) through a single clear corneal microincision.

OMNI is indicated by the FDA for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. OMNI has a CE Mark for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

OMNI should not be used in any situations where the iridocorneal angle is compromised or has been damaged since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris or in quadrants with previous MIGS implants.

OMNI received its first FDA clearance in 2017 and is protected by a global patent portfolio including 32 issued patents worldwide. OMNI is a registered trademark of Sight Sciences.

For more information, visit www.OMNIsurgical.com

About the SION™ Surgical Instrument

The SION Surgical Instrument is the first bladeless device used in goniotomy. SION is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork by removing diseased tissue as the surgeon sweeps the instrument around Schlemm’s canal with a single smooth motion. The bladeless technology of SION was developed to improve safety and ease of use by eliminating the need to navigate sharp instrumentation within the eye’s anterior chamber and iridocorneal angle anatomy. The design features are intended to drive up the efficiency and completion of the excisional tissue removal procedure.

The SION Surgical Instrument is a sterile, single use, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. SION should not be used if there is inadequate corneal clarity, or poor visualization of angle structures or in any situations where the anterior chamber angle has been damaged (i.e., from trauma or surgery) or it may not be possible to pass the device through Schlemm’s canal. SION is contraindicated in patients: with angle recession, neovascular glaucoma, chronic angle closure, narrow angle glaucoma, narrow inlets with plateau iris, peripheral anterior synechiae, traumatic, malignant, or uveitic glaucoma; it is also contraindicated in patients who have had previous argon laser trabeculoplasty, ab interno devices implanted in or through Schlemm’s Canal, or prior incisional glaucoma surgery including trabeculotomy, goniotomy.

SION is classified as a Class I 510(k) exempt device, in accordance with FDA regulations and guidance. SION is a trademark of Sight Sciences.

For more information, visit www.SIONsurgical.com.

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The SION Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

For more information, visit www.SightSciences.com.

Media Contact – Glaucoma

Carmen Caricchio
C2M Group
[email protected]

Investor contact

Philip Taylor
Gilmartin Group
415.937.5406
[email protected]



Jefferies to Host Investor Day on October 12, 2022

Jefferies to Host Investor Day on October 12, 2022

NEW YORK–(BUSINESS WIRE)–
As previously announced, Jefferies Financial Group Inc. (NYSE: JEF) (“Jefferies”) will host its annual Investor Day on Wednesday, October 12, 2022, at 9:00 a.m. in Manhattan. The meeting will include management presentations from Richard B. Handler, our Chief Executive Officer, Brian P. Friedman, our President, and leaders of our major businesses, as well as an opportunity to present questions to management.

To register for the event, which will be hosted both in-person and virtually, attendees should provide their contact information via https://www.jefferies.com/investormeeting2022 by 2:00 p.m. EST on October 10, 2022. Only registered guests will be allowed to participate.

About Jefferies

Jefferies is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies, and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research, and wealth management services across all products in the Americas, Europe, and Asia. Jefferies’ Leucadia Asset Management division is a growing alternative asset management platform.

Source: Care of Jefferies Financial Group Inc. and Jefferies Group LLC

For further information, please contact:

Jefferies Financial Group Inc.:

Laura Ulbrandt (212) 460-1977

or

Jefferies Group LLC:

Jonathan Freedman (212) 778-8913

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

LOS ALTOS, Calif.–(BUSINESS WIRE)–
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced Ripal Gandhi, M.D., FSIR, FSVM presented, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” at the recent Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi is a course director for the symposium recently held September 23-25, 2022 at the Loews Hotel in Miami Beach, Florida. View Dr. Gandhi’s full presentation.

Dr. Gandhi is a professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine. Since 2018, Dr. Gandhi has been instrumental in the multi-center Phase 3 TIGeR-PaC clinical trial as a principal investigator for the Miami Cancer Institute.

Dr. Gandhi’s presentation, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” provides an overview of the clinical challenges of the standard-of-care treatment, available to locally advanced pancreatic cancer (LAPC) patients. Systemic (intravenous) chemotherapy is considered the standard of care for LAPC and is often associated with debilitating side effects. It may be ineffective in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy.

Dr. Gandhi highlighted the RenovoTAMP therapy platform’s potential as a targeted oncology option for LAPC patients. The presentation showcased RenovoRx’s RR1 Phase I/II and RR2 Observational Registry studies suggesting when RenovoTAMP is used in combination with radiation therapy, arterial microvasculature may be reduced, minimizing chemotherapy leakage during delivery. Increasing chemotherapy directly to the tumor could reduce systemic side effects. Dr. Gandhi also presented about the mission and protocol behind the TIGeR-PaC study.

The TIGeR-PaC study is evaluating RenovoRx’s first product candidate, RenovoGem™, to treat LAPC through RenovoTAMP’s intra-arterial delivery of gemcitabine, an FDA-approved chemotherapy. Study goals include extension of patient survival, reduction of side-effects associated with systemic chemotherapy, and improved quality of life for pancreatic cancer patients.

“The CIO symposium aims to educate on the most viable and sought-after treatments in the rapidly growing practice of interventional oncology management,” said Ramtin Agah, M.D., Chief Medical Officer and Founder of RenovoRx. “As a recognized expert in this field, we appreciate Dr. Gandhi highlighting our therapy platform as a potential option for difficult-to-treat cancers, like LAPC.”

“Over the past decade, our team has refined RenovoTAMP. Results of Phase 1/2 and observational registry studies suggest RenovoTAMP may enhance patient survival while countering chemotherapy tolerability issues. The result could be improved quality of life for patients and their loved ones. Our team continues making progress enrolling the TIGeR-PaC study. We look forward to reporting the first prospective interim analysis for the study, which is expected in the fourth quarter of this year.”

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Learn more by visiting the RenovoRx website or following us on Facebook, LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoTAMPTM, RenovoCath® or RenovoGemTM or regarding our ongoing TIGeR-PaC Phase 3 clinical trial in LAPC, and statements regarding the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the ongoing COVID-19 pandemic on our operations; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Company Contact:

RenovoRx, Inc.

Shaun R. Bagai, CEO

James Ahlers, CFO

Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T :212-896-1254

[email protected]

Media Contact:

Knight Marketing Communications, Ltd.

Kevin Knight

T: 206-451-4823

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Radiology Health

MEDIA:

Logo
Logo

Trust Stamp Unveils Privtech™ – a New Government-Focused Privacy-First Identity Technology

Awarded Trademark by the US Patent and Trademark Office

Atlanta, GA, Sept. 28, 2022 (GLOBE NEWSWIRE) — T Stamp Inc. (“Trust Stamp” or the “Company”) (Nasdaq: IDAI, Euronext Growth: AIID ID), a global provider of AI-powered trust and identity services used globally across multiple sectors, today unveiled its new government-focused, privacy-first identity technology, Privtech™, and reports it has received registered trademark status for the Privtech solution by the US Patent and Trademark Office.

The technology provides four customizable levels of privacy protection using the Company’s existing Privtech Certified® structure and offers government agencies the ability to verify identity and protect against fraud, while minimizing the data collected and providing transparency as to its use. 

Gareth Genner, Chief Executive Officer of Trust Stamp, explained, “Privtech technology utilizes our patented irreversibly transformed identity token (IT2™), which allows users to be identified on a probabilistic basis without disclosing underlying biometric or other identity data. Within the Privtech Certified® structure there are four levels of privacy protection, of which Privtech Level Four is the most stringent with the entire enrollment and authentication processes taking place on the user’s own device, and only a randomized and encrypted one-time identifier ever leaving the device.” 

Dr. Norman Poh, Chief Science Officer of Trust Stamp, stated, “An IT2 can be created from virtually any modality of biometric together with most other types of identity data.  In addition to the obvious benefit of privacy protection, the IT2 has numerous advantages when compared to legacy biometric templates, including computational efficiency, interoperability and cancelability.”

Gareth Genner further noted, “Government agencies need to balance safe and efficient interaction with digital users against minimizing intrusion into the user’s privacy. Unlike the typical biometric systems in use today, Privtech Level Four does not require data intermediation by a private sector vendor and does not require the user to provide the agency with their biometric data. We have designed these solutions to meet the specific demands of government customers, which represent a very substantial and growing market opportunity.  Ultimately, we believe that Privtech Certified products will define a new privacy-first approach to interacting with government agencies.”

The Company’s announcement is in the wake of substantial increases in technology-focused investments by government agencies including $80 billion in new funding for the Internal Revenue Service with a stated emphasis on improving taxpayer services and modernizing the agency’s technology and other infrastructure.

About Trust Stamp

Trust Stamp, is a global provider of AI-powered identity services for use in multiple sectors including banking and finance, regulatory compliance, government, real estate, communications, and humanitarian services. Its technology empowers organizations with advanced biometric identity solutions that reduce fraud, protect personal data privacy, increase operational efficiency, and reach a broader base of users worldwide through its unique data transformation and comparison capabilities.

Located in seven countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI) and Euronext Growth in Dublin (Euronext Growth: AIID ID). Founded in 2016 by Gareth Genner and Andrew Gowasack, the company now employs over 100 people.

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Trust Stamp                                                      Email: [email protected]

Gareth Genner, Chief Executive Officer              

Davy (Euronext Growth Advisor)                       Tel: +353 1 679 6363 

Barry Murphy

Investor Relations                                            Tel: +1 212-671-1021

Crescendo Communications                              Email: [email protected]



Global Ship Lease Announces Adjourned Annual Meeting of Shareholders

LONDON, Sept. 28, 2022 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”) today announced that its scheduled Annual Meeting of Shareholders was convened on September 27, 2022, and has been subsequently adjourned due to lack of requisite quorum to October 7, 2022 at 6:00 p.m. local time, at 3-5 Menandrou Str., 14561 Kifisia, Athens, Greece.

The record date for determining shareholders entitled to participate at the Annual Meeting is August 2, 2022. The business of the Annual Meeting is to elect two Term II Directors to serve until the 2025 Annual Meeting of Shareholders and to ratify the appointment of PricewaterhouseCoopers S.A., as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. Annual Meeting documentation and instructions for voting were mailed to all shareholders of record on or about August 18, 2022 and have been furnished to the U.S. Securities and Exchange Commission (the “Commission”) and are available on the Commission’s website at www.sec.gov.

About Global Ship Lease

Global Ship Lease is a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships. Incorporated in the Marshall Islands, Global Ship Lease commenced operations in December 2007 with a business of owning and chartering out containerships under fixed-rate charters to top tier container liner companies. It was listed on the New York Stock Exchange in August 2008.

As at August 30, 2022, Global Ship Lease owned 65 containerships, ranging from 1,118 to 11,040 TEU, with an aggregate capacity of 342,348 TEU. 32 ships are wide-beam Post-Panamax.

Adjusted to include all charters agreed, up to August 30, 2022, the average remaining term of the Company’s charters as at June 30, 2022, to the mid-point of redelivery, including options under the Company’s control and other than if a redelivery notice has been received, was 3.1 years on a TEU-weighted basis. Contracted revenue on the same basis was $2.4 billion. Contracted revenue was $2.8 billion, including options under charterers’ control and with latest redelivery date, representing a weighted average remaining term of 4.0 years.

Investor and Media Contact:
The IGB Group
Bryan Degnan
646-673-9701
or
Leon Berman
212-477-8438



Paychex, Inc. Reports First Quarter Results: Double Digit Growth in Revenue and Diluted Earnings Per Share; Raises Earnings Outlook for the Year

Paychex, Inc. Reports First Quarter Results: Double Digit Growth in Revenue and Diluted Earnings Per Share; Raises Earnings Outlook for the Year

ROCHESTER, N.Y.–(BUSINESS WIRE)–Paychex, Inc. (the “Company,” “Paychex,” “we,” “our,” or “us”) today announced the following results for the quarter ended August 31, 2022 (the “first quarter”), as compared to the corresponding prior year period:

 

 

For the three months ended

 

 

 

 

 

August 31,

 

 

 

In millions, except per share amounts

 

2022

 

 

2021

 

Change(2)

Total service revenue

 

$

 

1,188.3

 

 

$

 

1,068.4

 

 

11

%

Total revenue

 

$

 

1,206.2

 

 

$

 

1,082.9

 

 

11

%

Operating income

 

$

 

495.6

 

 

$

 

442.9

 

 

12

%

Diluted earnings per share

 

$

 

1.05

 

 

$

 

0.92

 

 

14

%

Adjusted diluted earnings per share(1)

 

$

 

1.03

 

 

$

 

0.89

 

 

16

%

(1)

Adjusted diluted earnings per share is not a United States (“U.S.”) generally accepted accounting principle (“GAAP”) measure. Please refer to the “Non-GAAP Financial Measures” section on page 3 of this press release for a discussion of non-GAAP measures.

(2)

Percentage changes are calculated based on unrounded numbers.

Martin Mucci, Chairman and CEO, commented, “We are off to a good start for fiscal 2023, achieving double-digit growth in revenue and earnings. The value proposition of our Human Capital Management (“HCM”) technology and Paychex HR suite continues to resonate in the market, with notable strength in our mid-market, retirement, and HR solutions businesses.

“Businesses continue to look for HR technology to help them streamline payroll and benefits administration and more effectively recruit, retain, and manage their talent. At the HR Technology Conference and Exposition this month, we were pleased to provide attendees with an interactive experience highlighting the capabilities of our Paychex Flex HR Tech platform and how Paychex solutions can be customized to address their business challenges. In addition, we launched Paychex Voice Assist, a conversational artificial intelligence feature of Paychex Flex that allows payroll to be run through any Google Assistant-compatible device – a first in the industry. At Paychex, we are constantly monitoring data, market challenges, and consumer technology trends to innovate to meet the needs of our clients.”

First Quarter Business Highlights

Service revenue increased to $1.2 billion in the first quarter, an increase of 11% over the prior year period. Highlights as compared to the corresponding prior year period are as follows:

Management Solutions revenue was $905.5 million, an increase of 12%, led by the following factors:

  • Growth in the number of client employees served for HCM and additional worksite employees for HR Solutions;
  • Improved revenue per client resulting from price realization and higher product penetration, including strong demand for HR Solutions, retirement, and time and attendance solutions; and
  • Expansion of HCM ancillary services.

Professional Employer Organization (“PEO”) and Insurance Solutions revenue was $282.8 million, an increase of 8%, primarily due to the following:

  • Growth in the number of average worksite employees; and
  • Increase in PEO health insurance revenue.

Total expenses increased 11% to $710.6 million, as a result of the following:

  • Higher compensation costs due to increases in headcount and wage rates; and
  • PEO direct insurance costs increased as a result of higher health insurance enrollment.

Operating income grew 12% to $495.6 million as compared to the prior year period. Operating margin (operating income as a percentage of total revenue) of 41% increased compared to the prior year period.

Our effective income tax rate was 22.9% compared to 24.9% for the prior year period. Both periods were impacted by the recognition of excess tax benefits related to employee stock-based compensation payments. The prior year period was also impacted by an increase in state taxes.

Diluted earnings per share increased 14% to $1.05 per share for the first quarter compared to the prior year period. Adjusted diluted earnings per share(1) increased 16% to $1.03 per share for the first quarter compared to the prior year period.

(1) Adjusted diluted earnings per share is not a U.S. GAAP measures. Please refer to the “Non-GAAP Financial Measures” section on page 3 of this press release for a discussion of these non-GAAP measures.

Financial Position and Liquidity

Our financial position and cash flow generation remained strong. As of August 31, 2022, we had:

  • Cash, restricted cash, and total corporate investments of $1.3 billion.
  • Short-term and long-term borrowings, net of debt issuance costs, of $808.1 million.
  • Cash flow from operations was $364.3 million for the first quarter.

Return to Stockholders in the First Quarter

  • Paid dividends of $0.79 per share totaling $284.6 million.

Non-GAAP Financial Measures

 

 

For the three months ended

 

 

 

 

 

 

August 31,

 

 

 

 

$ in millions

 

2022

 

 

2021

 

 

Change

Net income

 

$

 

379.2

 

 

$

 

333.6

 

 

 

14

%

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to employee stock-based compensation payments(1)

 

 

 

(7.3

)

 

 

 

(10.4

)

 

 

 

Adjusted net income

 

$

 

371.9

 

 

$

 

323.2

 

 

 

15

%

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share(2)

 

$

 

1.05

 

 

$

 

0.92

 

 

 

14

%

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to employee stock-based compensation payments(1)

 

 

 

(0.02

)

 

 

 

(0.03

)

 

 

 

Adjusted diluted earnings per share

 

$

 

1.03

 

 

$

 

0.89

 

 

 

16

%

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

 

379.2

 

 

$

 

333.6

 

 

 

14

%

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

 

3.7

 

 

 

 

9.0

 

 

 

 

Income taxes

 

 

 

112.8

 

 

 

 

110.3

 

 

 

 

Depreciation and amortization expense

 

 

 

44.0

 

 

 

 

45.7

 

 

 

 

Total non-GAAP adjustments

 

 

 

160.5

 

 

 

 

165.0

 

 

 

 

EBITDA

 

 

 

539.7

 

 

 

 

498.6

 

 

 

8

%

(1)

Excess tax benefits related to employee stock-based compensation payments recognized in income taxes. This item is subject to volatility and will vary based on employee decisions on exercising employee stock options and fluctuations in our stock price, neither of which is within the control of management.

(2)

The calculation of the impact of non-GAAP adjustments on diluted earnings per share is performed on each line independently. The table may not add down by +/- $0.01 due to rounding.

In addition to reporting net income, and diluted earnings per share, which are U.S. GAAP measures, we present adjusted net income, adjusted diluted earnings per share, and earnings before interest, taxes, depreciation, and amortization (“EBITDA”), which are non-GAAP measures. We believe these additional measures are indicators of our core business operations’ performance period over period. Adjusted net income, adjusted diluted earnings per share, and EBITDA, are not calculated through the application of U.S. GAAP and are not required forms of disclosure by the Securities and Exchange Commission (“SEC”). As such, they should not be considered a substitute for the U.S. GAAP measures of net income, and diluted earnings per share, and, therefore, they should not be used in isolation but in conjunction with the U.S. GAAP measures. The use of any non-GAAP measure may produce results that vary from the U.S. GAAP measure and may not be comparable to a similarly defined non-GAAP measure used by other companies.

Business Outlook

Our outlook for the fiscal year ending May 31, 2023 (“fiscal 2023”) incorporates current assumptions and market conditions. Changes in the macroeconomic environment could alter our guidance. With consideration of these impacts, we have updated our guidance as follows:

  • Adjusted diluted earnings per share(1) is now anticipated to grow in the range of 11% to 12%.
  • Other aspects of our guidance for fiscal 2023 remain unchanged from what we provided previously.

(1) Adjusted EBITDA margin and adjusted diluted earnings per share are not U.S. GAAP measures. EBITDA margin is calculated as net income, adjusted for interest, taxes, depreciation, and amortization as a percentage of total revenue. Please refer to the “Non-GAAP Financial Measures” section on page 4 of this press release for a discussion of these non-GAAP measures.

Environmental, Social, and Governance (“ESG”)

As part of what it means to be Paychex, we are focusing our ESG efforts on actions we can take to create positive impact. To learn more about our latest initiatives, please see our Environmental, Social, and Governance Report. The information available on our website is not a part of, and is not incorporated into, this press release.

Quarterly Report on Form 10-Q (“Form 10-Q”)

We anticipate filing our Form 10-Q for the first quarter within the next day, and it will be available at Paychex Investor Relations portal. This press release should be read in conjunction with the Form 10-Q and the related Notes to Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in that Form 10-Q.

Webcast Details

Interested parties may access the webcast of our Earnings Release Conference Call, scheduled for September 28, 2022, at 9:30 a.m. Eastern Time, at Paychex Investor Relations portal. The webcast will be archived for approximately 90 days. Our news releases, current financial information, SEC filings, and investor presentations are also accessible at Paychex Investor Relations portal.

About Paychex

Paychex, Inc. (Nasdaq:PAYX) is a leading provider of integrated human capital management solutions for human resources, payroll, benefits, and insurance services. By combining innovative software-as-a-service technology and mobility platform with dedicated, personal service, Paychex empowers business owners to focus on the growth and management of their business. Backed by 50 years of industry expertise, Paychex serves more than 730,000 payroll clients as of May 31, 2022 in the U.S. and Europe, and pays one out of every 12 American private sector employees. Learn more about Paychex by visiting www.paychex.com and stay connected on Twitter (Twitter) and LinkedIn (LinkedIn).

Cautionary Note Regarding Forward-Looking Statements

Certain written and oral statements made by us may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by such words and phrases as “expect,” “estimate,” “intend,” “overview,” “outlook,” “guidance,” “we look forward to,” “will,” “would,” “project,” “projections,” “strategy,” “anticipate,” “believe,” “could,” “may,” “target,” “potential,” “strive,” “mission,” and other similar words or phrases. Examples of forward-looking statements include, among others, statements we make regarding operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to our outlook, revenue growth, earnings, earnings-per-share growth, or similar projections.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance upon any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

  • our ability to keep pace with changes in technology or provide timely enhancements to our products and services;
  • software defects, undetected errors, and development delays for our products;
  • the possibility of cyberattacks, security vulnerabilities or Internet disruptions, including data security and privacy leaks and data loss and business interruptions;
  • the possibility of failure of our business continuity plan during a catastrophic event;
  • the failure of third-party service providers to perform their functions;
  • the possibility that we may be exposed to additional risks related to our co-employment relationship with our PEO business;
  • changes in health insurance and workers’ compensation insurance rates and underlying claim trends;
  • risks related to acquisitions and the integration of the businesses we acquire;
  • our clients’ failure to reimburse us for payments made by us on their behalf;
  • the effect of changes in government regulations mandating the amount of tax withheld or the timing of remittances;
  • our failure to comply with covenants in our debt agreements;
  • changes in governmental regulations and policies;
  • our ability to comply with U.S. and foreign laws and regulations;
  • our compliance with data privacy laws and regulations;
  • our failure to protect our intellectual property rights;
  • potential outcomes related to pending or future litigation matters;
  • the impact of the COVID-19 pandemic and other macroeconomic factors on the U.S. and global economy, and in particular on our small- and medium-sized business clients;
  • volatility in the political and economic environment, including rising inflation;
  • changes in the availability and retention of qualified people; and
  • the possible effects of negative publicity on our reputation and the value of our brand.

Any of these factors, as well as such other factors as discussed in our SEC filings, could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known as of the date of this press release, and any forward-looking statements made by us in this document speak only as of the date on which they are made. Except as required by law, we undertake no obligation to update these forward-looking statements after the date of issuance of this press release to reflect events or circumstances after such date, or to reflect the occurrence of unanticipated events.

PAYCHEX, INC.

CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(In millions, except per share amounts)

 

 

 

For the three months ended

 

 

 

 

 

 

August 31,

 

 

 

 

 

 

2022

 

 

2021

 

 

Change(2)

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Management Solutions

 

$

 

905.5

 

 

$

 

805.5

 

 

 

12

%

PEO and Insurance Solutions

 

 

 

282.8

 

 

 

 

262.9

 

 

 

8

%

Total service revenue

 

 

 

1,188.3

 

 

 

 

1,068.4

 

 

 

11

%

Interest on funds held for clients(1)

 

 

 

17.9

 

 

 

 

14.5

 

 

 

24

%

Total revenue

 

 

 

1,206.2

 

 

 

 

1,082.9

 

 

 

11

%

Expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of service revenue

 

 

 

351.0

 

 

 

 

312.5

 

 

 

12

%

Selling, general and administrative expenses

 

 

 

359.6

 

 

 

 

327.5

 

 

 

10

%

Total expenses

 

 

 

710.6

 

 

 

 

640.0

 

 

 

11

%

Operating income

 

 

 

495.6

 

 

 

 

442.9

 

 

 

12

%

Other (expense)/income, net(1)

 

 

 

(3.6

)

 

 

 

1.0

 

 

n/m

 

Income before income taxes

 

 

 

492.0

 

 

 

 

443.9

 

 

 

11

%

Income taxes

 

 

 

112.8

 

 

 

 

110.3

 

 

 

2

%

Net income

 

$

 

379.2

 

 

$

 

333.6

 

 

 

14

%

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

 

1.05

 

 

$

 

0.93

 

 

 

13

%

Diluted earnings per share

 

$

 

1.05

 

 

$

 

0.92

 

 

 

14

%

Weighted-average common shares outstanding

 

 

 

360.1

 

 

 

 

360.1

 

 

 

 

Weighted-average common shares outstanding, assuming dilution

 

 

 

362.4

 

 

 

 

362.8

 

 

 

 

(1)

Further information on interest on funds held for clients and other expense, net, and the short- and long-term effects of changing interest rates can be found in our filings with the SEC, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, as applicable, under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and subheadings “Results of Operations” and “Market Risk Factors.” These filings are accessible at www.paychex.com.

(2)

Percentage changes are calculated based on unrounded numbers.
n/m – not meaningful

PAYCHEX, INC.

CONSOLIDATED BALANCE SHEETS (Unaudited)

(In millions, except per share amounts)

 

 

August 31,

 

 

May 31,

 

 

2022

 

 

2022

 

ASSETS

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

1,184.2

 

 

$

 

370.0

 

Restricted cash

 

 

 

60.1

 

 

 

 

50.3

 

Corporate investments

 

 

 

45.8

 

 

 

 

853.9

 

Interest receivable

 

 

 

20.6

 

 

 

 

22.3

 

Accounts receivable, net of allowance for credit losses

 

 

 

876.4

 

 

 

 

723.8

 

PEO unbilled receivables, net of advance collections

 

 

 

476.3

 

 

 

 

572.1

 

Prepaid income taxes

 

 

 

 

 

 

 

34.0

 

Prepaid expenses and other current assets

 

 

 

286.2

 

 

 

 

272.3

 

Current assets before funds held for clients

 

 

 

2,949.6

 

 

 

 

2,898.7

 

Funds held for clients

 

 

 

3,135.8

 

 

$

 

3,682.9

 

Total current assets

 

 

 

6,085.4

 

 

 

 

6,581.6

 

Long-term restricted cash

 

 

 

32.6

 

 

 

 

25.5

 

Long-term corporate investments

 

 

 

3.9

 

 

 

 

5.0

 

Property and equipment, net of accumulated depreciation

 

 

 

398.1

 

 

 

 

401.3

 

Operating lease right-of-use assets, net of accumulated amortization

 

 

 

74.7

 

 

 

 

78.7

 

Intangible assets, net of accumulated amortization

 

 

 

212.5

 

 

 

 

224.6

 

Goodwill

 

 

 

1,825.3

 

 

 

 

1,831.5

 

Long-term deferred costs

 

 

 

441.1

 

 

 

 

433.3

 

Other long-term assets

 

 

 

52.3

 

 

 

 

53.7

 

Total assets

 

$

 

9,125.9

 

 

$

 

9,635.2

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

35.1

 

 

$

 

49.5

 

Accrued corporate compensation and related items

 

 

 

138.7

 

 

 

 

225.4

 

Accrued worksite employee compensation and related items

 

 

 

715.0

 

 

 

 

683.4

 

Short-term borrowings

 

 

 

10.3

 

 

 

 

8.7

 

Accrued income taxes

 

 

 

40.0

 

 

 

 

 

Deferred revenue

 

 

 

40.8

 

 

 

 

38.4

 

Other current liabilities

 

 

 

411.0

 

 

 

 

444.6

 

Current liabilities before client fund obligations

 

 

 

1,390.9

 

 

 

 

1,450.0

 

Client fund obligations

 

 

 

3,311.3

 

 

 

 

3,819.2

 

Total current liabilities

 

 

 

4,702.2

 

 

 

 

5,269.2

 

Accrued income taxes

 

 

 

61.7

 

 

 

 

58.1

 

Deferred income taxes

 

 

 

157.1

 

 

 

 

165.5

 

Long-term borrowings, net of debt issuance costs

 

 

 

797.8

 

 

 

 

797.7

 

Operating lease liabilities

 

 

 

71.0

 

 

 

 

74.8

 

Other long-term liabilities

 

 

 

198.7

 

 

 

 

184.7

 

Total liabilities

 

 

 

5,988.5

 

 

 

 

6,550.0

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Common stock, $0.01 par value; Authorized: 600.0 shares; Issued and outstanding: 360.4 shares as of August 31, 2022 and 359.9 shares as of May 31, 2022

 

 

 

3.6

 

 

 

 

3.6

 

Additional paid-in capital

 

 

 

1,568.9

 

 

 

 

1,545.9

 

Retained earnings

 

 

 

1,736.3

 

 

 

 

1,669.6

 

Accumulated other comprehensive loss

 

 

 

(171.4

)

 

 

 

(133.9

)

Total stockholders’ equity

 

 

 

3,137.4

 

 

 

 

3,085.2

 

Total liabilities and stockholders’ equity

 

$

 

9,125.9

 

 

$

 

9,635.2

 

PAYCHEX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(In millions)

 

 

For the three months ended

 

 

 

August 31,

 

 

 

2022

 

 

2021

 

OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

Net income

 

$

 

379.2

 

 

$

 

333.6

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 

44.0

 

 

 

 

45.7

 

Amortization of premiums and discounts on available-for-sale (“AFS”) securities, net

 

 

 

6.0

 

 

 

 

7.9

 

Amortization of deferred contract costs

 

 

 

53.0

 

 

 

 

49.1

 

Stock-based compensation costs

 

 

 

14.4

 

 

 

 

12.4

 

Provision for deferred income taxes

 

 

 

2.5

 

 

 

 

11.5

 

Provision for credit losses

 

 

 

4.5

 

 

 

 

(3.6

)

Net realized gains on sales of AFS securities

 

 

 

(0.1

)

 

 

 

(0.1

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Interest receivable

 

 

 

1.7

 

 

 

 

3.1

 

Accounts receivable and PEO unbilled receivables, net

 

 

 

(61.2

)

 

 

 

(30.4

)

Prepaid expenses and other current assets

 

 

 

23.7

 

 

 

 

23.2

 

Accounts payable and other current liabilities

 

 

 

(61.1

)

 

 

 

(29.1

)

Deferred costs

 

 

 

(64.5

)

 

 

 

(53.7

)

Net change in other long-term assets and liabilities

 

 

 

23.7

 

 

 

 

17.6

 

Net change in operating lease right-of-use assets and liabilities

 

 

 

(1.5

)

 

 

 

(1.6

)

Net cash provided by operating activities

 

 

 

364.3

 

 

 

 

385.6

 

INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Purchases of AFS securities

 

 

 

(3,807.6

)

 

 

 

(247.5

)

Proceeds from sales and maturities of AFS securities

 

 

 

5,066.9

 

 

 

 

256.9

 

Purchases of property and equipment

 

 

 

(30.6

)

 

 

 

(30.4

)

Purchases of other assets

 

 

 

(5.6

)

 

 

 

(1.3

)

Net cash provided by/(used in) investing activities

 

 

 

1,223.1

 

 

 

 

(22.3

)

FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Net change in client fund obligations

 

 

 

(507.9

)

 

 

 

32.4

 

Net change in short-term borrowings

 

 

 

2.0

 

 

 

 

(0.3

)

Dividends paid

 

 

 

(284.6

)

 

 

 

(238.1

)

Repurchases of common shares

 

 

 

 

 

 

 

 

Activity related to equity-based plans

 

 

 

(19.2

)

 

 

 

(5.7

)

Net cash used in financing activities

 

 

 

(809.7

)

 

 

 

(211.7

)

Net change in cash, restricted cash, and equivalents

 

 

 

777.7

 

 

 

 

151.6

 

Cash, restricted cash, and equivalents, beginning of period

 

 

 

928.4

 

 

 

 

1,823.1

 

Cash, restricted cash, and equivalents, end of period

 

$

 

1,706.1

 

 

$

 

1,974.7

 

 

 

 

 

 

 

 

 

 

Reconciliation of cash, restricted cash, and equivalents

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

1,184.2

 

 

$

 

1,102.0

 

Restricted cash

 

 

 

92.7

 

 

 

 

83.6

 

Restricted cash and restricted cash equivalents included in funds held for clients

 

 

 

429.2

 

 

 

 

789.1

 

Total cash, restricted cash, and equivalents

 

$

 

1,706.1

 

 

$

 

1,974.7

 

 

For more information:

Investor Relations: Efrain Rivera, CFO, or Terri Allen

585‑383‑3406

Media Inquiries: Chris Muller, Director, Corporate Communications

585‑338-4346

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Other Professional Services Insurance Human Resources Finance Professional Services Technology Mobile/Wireless Other Technology

MEDIA: